Immunoassay for Serum Glutamine Synthetase in Serum: Development, Reference Values, and Preliminary Study in Dementias, Miyoko Takahashi, * Eric Stanton, J. Ignacio Moreno, and George Jackowski (Syn-X Pharma Inc., 6354 Viscount Rd., Mississauga, Ontario, L4V 1H3 Canada; * author for correspondence: fax 905-677-1674, e-mail empty@ICA.net) Glutamine synthetase (GS) is a ubiquitous enzyme present at high concentrations in liver, muscle, kidney, and brain (1 ) . GS in the brain is astrocyte specific, is involved in the detoxification of ammonia and glutamate, and is overexpressed after brain injury (2 ) . Monomeric GS protein was found in 38 of 39 cerebrospinal fluid samples obtained from Alzheimer disease (AD) patients (3 ) , and the concentration of GS in the lumbar cerebral spinal fluid of AD patients was increased significantly but nonspecifically (4 ) . GS has also been reported in serum (4 ) .
Markers for AD have poor sensitivity and specificity for overt or preclinical AD (5, 6 ) . We have developed an ELISA that is rapid, highly sensitive, and GS specific. This ELISA, together with the S100B and neuron-specific enolase (NSE) ELISAs, was used to retrospectively assess serum GS in healthy controls, AD patients, and other dementia patients.
Recombinant human GS (rhGS) cDNA was purchased from ATCC (ATCC No. 409071). The full-length rhGS open reading frame was obtained by PCR and subcloning in pET28a (Ndel/XhoI). The construct included a polyhistidine tag at the N-terminal domain of the rhGS open reading frame and no extra sequence at the C-terminal domains. The protein was expressed in E. coli BL21 (DE3) (7 ) . We prepared extracts and solubilized products as described (8 ) . Affinity purification was performed by nickel-nitrilotriacetic acid chromatography.
Female Balb/c mice (7-8 weeks of age) were immunized by subcutaneous injection of 50 g of rhGS emulsified in complete Freund's adjuvant. An intraperitoneal booster injection was given 3 weeks later (50 g in incomplete Freund's adjuvant) and then at 2-to 3-week intervals (three times or more) with a final injection of 50 g of antigen in buffer via intraperitoneal route 3 days before cell fusion. Hybridoma cultures were screened by ELISA, and positive cultures were cloned at least twice with limiting dilutions as described (9 ) . Monoclonal antibodies (MAbs) were purified by protein G chromatography (Phamacia Biotech), and subclass was determined (Mouse Typer ® ; Bio-Rad). Serum S100B and NSE ␥␥ were analyzed by two ELISAs (SMART S100B and SMART NSE; Syn-X Pharma, Inc.). For GS, MaxiSorp TM plates (NUNC) were coated for 16 -24 h at 4-8°C with 10 mg/L MAb 1G3 in 0.125 mL/well of coating buffer (20 mmol/L NaHPO 4 buffer, pH 7.4). The plates were washed once with wash buffer (phosphate-buffered saline containing 0.5 g/L Tween 20, pH 7.4), followed by another wash with phosphatebuffered saline, pH 7.4, and the free binding sites were blocked at room temperature for 1 h with 0.25 mL of Box whisker plots depict the 25th and 75th percentiles (lower and upper edges of box, respectively) and the 10th and 90th percentiles (line extending below and above box, respectively). The 95.7 percentile, as calculated for the sample population (n ϭ 145), is represented by a dashed line above the total box plot.
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blocking buffer (phosphate-buffered saline containing 5 g/L bovine serum albumin), after which time the plates were washed three times. rhGS was used as the calibrator. The purified rhGS was quantified by the Bradford method (Bio-Rad). The rhGS stock solution was diluted to 100 g/L in the calibrator diluent (human serum from a pool of 15 apparently healthy donors) and kept frozen in 100-L aliquots at Ϫ75°C until use. After thawing, the rhGS solution was diluted further to 0 -2 g/L in the diluent supplemented immediately before use with 4 mmol/L Pefa-blocSC and PSC-protector (Boehringer Mannheim) and 1 mL/L ProClin-300 (Supelco) followed by filtration through a sterile 0.2-m membrane.
Incubation steps of the ELISA were at room temperature on an orbital shaker unless otherwise stated. Calibrators and serum samples were pipetted in duplicate at 50 Table 1 . Serum GS, S100B, and NSE in AD patient samples and samples from patients with dementia other than AD. From three cell fusions, 13 clones were established: 1 produced IgM, k; 1 IgA, k; 4 IgG2b, k; and 7 IgG1, k. None cross-reacted with any isoform of S100 protein, NSE ␥␥ , NSE ␣␣ , myelin basic protein, or glial fibrillary acidic protein at 10 mg/L in the ELISA. Pairing analysis was performed on all clones, using a BIAcore biosensor, and two IgG1 clones, 1G3 and 5G4, were chosen for ELISA assay development. To examine the specificity for brain GS, cross-reactivities of the selected capture MAb (1G3) were tested by Western blotting against brain, liver, and muscle tissue extracts with 5 g of protein. MAb 1G3 reacted with only the brain GS (data not shown). The total GS assay time was 80 min with a detection limit of 0.017 g/L GS (zero calibrator, ϩ 2 SD; n ϭ 20). The calibration curve was 0 -2 g/L. Intraassay (n ϭ 32) and interassay (n ϭ 20) imprecision (CV) was assessed with a pool of four serum samples with 0.15 and 1 g/L added rhGS. The maximum CV was 7.25%. No hook effect was observed at a GS concentration of 500 g/L, although the ELISA signal reached its maximum at 100 g/L. Recovery of rhGS (0.15 and 0.4 g/L) added to three sera was 90 -103% (mean, 97%). To assess linearity, four patient sera with high GS, diluted with the zero calibrator (to 2-, 4-, 8-, and 16-fold dilutions), were measured in triplicates.
The measured values were 87-112% of those expected. In serum and plasma samples from six blood donors with added rhGS (0.5 g/L), heparin plasma results were 84 -97% of serum values, citrated plasma results were 90 -108% of serum, and EDTA plasma results were 120 -146% of serum values.
We obtained serum from 153 healthy donors (18 -87 years; mean, 71 Ϯ 10 years): 80 were from employees of Syn-X Pharma Inc.; 40 were purchased from Intergen (donors with no known medical conditions); and 33 samples were age-matched controls from the clinics where samples from dementia patients were obtained. For reference values, we used the mean ϩ2 SD: GS ϭ 0.022 g/L, S100B ϭ 0.02 g/L, and NSE ϭ 8.34 g/L.
Serum The diagnoses of AD and other dementia were made by clinicians blinded to the biochemical marker results. Likewise, the technologists performing biochemical marker assays were blinded to the diagnosis of patients. Exclusion criteria (part of the Institutional Review Board protocol) were as follows: cerebral tumor, hypothyroidism, vitamin B 12 deficiency, dementia by chronic substance abuse, and HIV-related dementia. The mean age of the patients with dementia was 74 Ϯ 11 years (range, 53-91 years). Blood samples were obtained and centrifuged after clotting; aliquots of sera were stored frozen at Ϫ75°C until analysis. Institutional Review Board approval was obtained to collect blood samples, and each study participant or their power of attorney signed an informed consent form.
Healthy individuals in the sixth decade had higher mean concentrations of GS than those in other decades ( Fig. 1; P Ͻ0 .001, Tukey-Kramer honestly significant difference test). Those with high GS in the sixth decade may have had undiagnosed AD, whereas AD patients in the seventh decade had developed clinical signs, which would have excluded them from the healthy population.
Serum GS did not differ between sexes. Results in patients are shown in Table 1 . GS correlated with the severity of AD, i.e., Mini-Mental State Examination score (r ϭ 0.65), whereas no significant correlation was observed with NSE. The positivity rate of S100B was very low, but when this marker is increased, it may be an indication of ongoing destruction of astrocytes in the brain attributable to acute events as observed in patients AD-10 and AD-18.
Of the 14 non-AD dementia samples, only 1 had increased concentrations of both GS and S100B, whereas 7 samples had increased NSE (Table 1 ). The GS-positive patient (DC-008) with dementia with Lewy bodies may have had undetected AD; many patients with Lewy body dementia have concomitant AD pathology (10 ). The area under the ROC curve for GS was 0.950 (SE, 0.021; 95% confidence interval, 0.911-0.975).
Although the increase of NSE is not specific for AD, NSE may contribute as an indicator of the ongoing destruction of neurons that occurs in AD (11 ) . GS is a sensitive and specific marker for AD when the protein is analyzed in blood. The serum concentration of S100B is not increased in most dementia patients, but it may indicate acute events (e.g., transient ishemic attack, stroke, and hypoxia leading to ischemia), which are common among older individuals who are the target population of Most immunoassays are based on microtiter plates with conventional polystyrene (PS) as a solid support. PS is produced from crude oil. The production of PS plates consumes several hundred thousands tons of valuable raw material of limited supply. Also, disposing of PS plates by incineration produces a complex mixture of pollutants including dioxins and polycyclic aromatic hydrocarbons (1 ), and it adds excess CO 2 to the atmosphere.
In contrast, biopolymers such as polylactic acids (PLAs) are produced from renewable resources; they are biodegradable and their CO 2 balance is neutral. PLA-based polymers have successfully replaced synthetic polymers in several applications, including some recent applications in immunology (2, 3 ) . For the development of a PLA formula suitable as a matrix for immunoassays, the physical properties and surface characteristics of the polymer had to be improved for the present study. Surface characteristics are affected by factors such as monomer content, the nature and concentration of various additives, and molding and releasing conditions. Moreover, lot-tolot reproducibility is affected by industrial fermentation and extraction procedures.
For this study, the injection-molding process commonly used for PS was adapted to the PLA polymer to produce an experimental batch of 96-well microtiter plates from suitable PLA formulations. The performance of these plates in an ELISA was compared with conventional commercial PS plates.
We used recombinant measles virus hemagglutinin protein (H-ELISA) as antigen for the detection of measlesspecific IgG (4 -6 ). We analyzed a panel of 426 human sera using 96-well prototype microtiter plates made of PLA. The procedure was applied essentially as described (5 ). All study participants or their parents gave informed consent. Results were compared with those obtained with the same antigen and commercial PS Maxisorp microtiter plates (NUNC).
Statistical analysis of data was performed with SigmaStat software (Jandel Scientific). A z-test was applied to compare two proportions (of a population) with a 95% confidence interval. The Mann-Whitney U-test was used to evaluate the significance between median values. The correlation coefficient (r) was obtained by linear regression analysis. The correlation coefficient () and the proportion of agreement were calculated according to the method of Bland and Altman (7 ) . The performance characteristics of the ELISAs were calculated following the definitions of Bland (8 ) . Sera were collected from 221 vaccinated high school children (12.1-15.1 years; median age, 12.7 years; 37 males and 184 females) and 194 adults, including 82 males (25-91 years; median, 42 years) and 112 females (25-78 years; median, 45 years), who had measles during their childhood. The children were vaccinated at least once against measles at the age of 4.7-148.9 months (median, 19.5 months). All sera were tested by plaque neutralization assay (NT) as described by Huiss et al. (9 ) ; NT titers were expressed as Ϫlog 2 of the dilution, with values of 1:2 4 being considered negative. This assay served as a gold standard (10, 11 ) . All of the above sera (n ϭ 415) were NT positive and further confirmed by a certified commercial ELISA (Enzygnost; Dade Behring). In addition, 11 NT-negative sera from seven unvaccinated 15-month-old children, two adolescents, and two adults were included.
The PLA formulation used for the production of the prototype plates had a slightly greenish coloration. The absorbance (mean Ϯ SD) at 405 nm of the empty wells (n ϭ 852) was 0.129 Ϯ 0.005 with a CV of 3.7%, which was
